DexCom, Inc. - Common Stock (NQ:DXCM)

Stelo Adds Enhanced Smart Meal Logging Features as Dexcom Continues to Transform Personal Glucose Management

February 04, 2026

From Dexcom, Inc.

Profitability is a key measure of business strength. Companies with high margins have proven they can generate consistent earnings while maintaining financial discipline.

3 Profitable Stocks for Long-Term Investors

January 28, 2026

Dexcom Schedules Fourth Quarter and Fiscal Year 2025 Earnings Release and Conference Call for February 12, 2026 at 4:30 p.m. Eastern Time.

DexCom Inc. (NASDAQ:DXCM) Combines Strong Fundamentals with Bullish Chart Pattern ↗

January 20, 2026

Via Chartmill

January 27, 2026

From DexCom, Inc.

Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. However, they face intense competition from...

2 Mid-Cap Stocks with Exciting Potential and 1 We Ignore

January 26, 2026

Abbott Laboratories (NYSE: ABT) saw its stock price tumble by nearly 10% in early trading on January 22, 2026, following the release of its fourth-quarter 2025 financial results. Despite meeting...

Abbott Laboratories Shares Plunge 10% Following Q4 Revenue Miss and Diagnostics Weakness

January 22, 2026

Via MarketMinute

Topics Economy

Abbott Shares Slump as Revenue Miss and Exact Sciences Acquisition Jitters Overshadow Earnings Beat

January 22, 2026

Abbott Laboratories (NYSE: ABT) saw its shares retreat by 5.8% in early trading on Thursday, January 22, 2026, following the release of its fourth-quarter financial results. Despite delivering an...

Via MarketMinute

Topics Earnings Economy

1 Growth Stock Down 19% to Buy Right Now ↗

January 21, 2026

It has had strong momentum since November, but there is still plenty of upside left.

Via The Motley Fool

Topics Product Recall

Halper Sadeh LLC Encourages DexCom, Inc. Shareholders to Contact the Firm to Discuss Their Rights

January 15, 2026

From Halper Sadeh LLC

Dexcom Reports Preliminary, Unaudited Results for the Fourth Quarter and Fiscal Year 2025 and Initial 2026 Outlook

Top S&P500 movers in Monday's session ↗

January 12, 2026

Via Chartmill

What's going on in today's session: S&P500 movers ↗

January 12, 2026

Via Chartmill

January 12, 2026

From DexCom, Inc.

Shares of medical device company DexCom (NASDAQ:DXCM) fell 2.6% in the morning session after analysts at Piper Sandler and Bernstein lowered their price targets on the stock, citing concerns over the...

DexCom (DXCM) Stock Trades Down, Here Is Why

January 08, 2026

Dexcom Enters Next Era of Continued Innovation With Jake Leach as President and Chief Executive Officer

Topics Artificial Intelligence

January 07, 2026

From DexCom, Inc.

The Nasdaq 100 (^NDX) is where investors find some of the most innovative and disruptive companies shaping the future. A select few continue to execute at a high level, growing their market dominance...

3 Nasdaq 100 Stocks Worth Your Attention

January 04, 2026

As of today, January 1, 2026, Abbott Laboratories (NYSE: ABT) stands as one of the most resilient and strategically diversified giants in the global healthcare landscape. While the broader market has...

The Evolution of a Healthcare Giant: Abbott Laboratories (ABT) 2026 Stock Feature

January 01, 2026

Via PredictStreet

Topics Economy Lawsuit World Trade

2 Healthcare Stocks for Long-Term Investors and 1 We Find Risky

December 31, 2025

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from elevated demand, which has supported the...

Neither had a great year in 2025, but the future is looking bright.

Topics Stocks

2 Growth Stocks to Buy For 2026 and Beyond ↗

December 30, 2025

Via The Motley Fool

Topics Economy

DexCom Inc (NASDAQ:DXCM) Embodies the Growth at a Reasonable Price (GARP) Strategy ↗

December 30, 2025

DexCom (DXCM) exemplifies Growth at a Reasonable Price (GARP) with strong double-digit earnings growth, solid profitability, and a valuation justified by its industry-leading position in diabetes...

Via Chartmill

DEXCOM CLASS ACTION DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds DXCM Investors of the December 26th Deadline for Contacting the Firm

December 26, 2025

From Bragar Eagel & Squire

DXCM Investors Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit with the Schall Law Firm

December 26, 2025

From Schall Law

The $65 Billion Pulse: How Wearable AI and Telemedicine are Redefining the Future of Healthcare

December 24, 2025

The convergence of consumer technology and clinical medicine has reached a fever pitch as 2025 draws to a close. A landmark report released this December by ResearchAndMarkets.com projects that the...

Via MarketMinute

Topics Artificial Intelligence

1 Cash-Heavy Stock for Long-Term Investors and 2 We Avoid

December 22, 2025

Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they struggle to grow or generate consistent profits,...

DEXCOM CLASS ACTION DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds DXCM Investors of the December 26th Deadline for Contacting the Firm

December 22, 2025

From Bragar Eagel & Squire

DXCM Deadline in 4 Days: Kessler Topaz Meltzer & Check, LLP Reminds DexCom, Inc. (DXCM) Investors of Filing Deadline in Class Action Lawsuit

December 22, 2025

Via TheNewswire.com

Topics Lawsuit

DXCM Deadline in 4 Days: Kessler Topaz Meltzer & Check, LLP Reminds DexCom, Inc. (DXCM) Investors of Filing Deadline in Class Action Lawsuit

December 22, 2025

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Lawsuit

DXCM Investors Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit with the Schall Law Firm

December 22, 2025

From Schall Law

SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against DexCom, Inc. (NASDAQ: DXCM)

December 22, 2025

From Bernstein Liebhard LLP